Antioxidant enzyme activities in hepatic tissue from children with chronic cholestatic liver disease

Nagwa A Ismail1, Sawsan H Okasha, A Dhawan

  • 1Department of Pediatrics, Medical Research Division, National Research Centre, Dokki, Egypt. nagwa_abdallah@yahoo.com

Insights

Children with cholestatic chronic liver disease show increased oxidative stress markers, including superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT). These findings suggest a role for oxidative stress in disease development.

Area of Science:

  • Pediatric Hepatology
  • Biochemistry
  • Oxidative Stress Research

Background:

  • Cholestatic chronic liver diseases in children are associated with significant morbidity.
  • The role of oxidative stress in the pathogenesis of these conditions remains incompletely understood.

Purpose of the Study:

  • To investigate the oxidative stress status in pediatric patients with cholestatic chronic liver disease.
  • To quantify the activity of key antioxidant enzymes: glutathione peroxidase (GPx), superoxide dismutase (SOD), and catalase (CAT) in liver tissue.

Main Methods:

  • A cohort of 34 children with cholestatic chronic liver disease underwent liver biopsy.
  • Control group comprised 7 children with incidental normal liver biopsies.
  • Enzyme activities (GPx, SOD, CAT) were measured in fresh liver tissue using ELISA.

Main Results:

  • Children with cholestatic liver disease exhibited significantly elevated hepatic levels of SOD, GPx, and CAT compared to controls.
  • Extrahepatic biliary atresia group showed significant increases in all three enzymes.
  • Neonatal hepatitis and paucity of intrahepatic bile ducts groups demonstrated significant increases in GPx and CAT.

Conclusions:

  • Oxidative stress is implicated in the pathogenesis of pediatric cholestatic chronic liver diseases.
  • Elevated antioxidant enzyme activity suggests a compensatory response to oxidative damage.
  • Further clinical studies exploring adjuvant antioxidant therapy are warranted.
Abstract

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...